Compare Bristol-Myers Squibb Co (BMY) vs First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Bristol-Myers Squibb Co trades at $57.81 (market cap $116.30B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $55.65. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while First Trust NASDAQ Clean Edge Green Energy Idx Fd pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals.
| BMY | QCLN | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $62.37 | $68.47 |
52-Week Low | $42.60 | $34.31 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
QCLN trades at $53.57, down 3.82% with bearish technical signals from moving averages. The clean energy ETF faces mixed sentiment as policy uncertainties from stalled US permits and China restrictions contrast with strong global investment trends. RSI levels suggest potential oversold conditions at 27.51, while ADX indicates strong bearish momentum. Support consolidates around $55 with resistance at $56-57.
The clean energy sector shows long-term growth potential amid energy security concerns and rising demand, but near-term headwinds from US policy uncertainty and supply chain costs create volatility. Investor sentiment remains cautious despite favorable industry tailwinds, requiring careful risk assessment of regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →
